FDA Office That Guided PDUFA V Gets New Name Highlighting Its Strategic Role
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Drug Evaluation and Research’s Office of Planning and Informatics has been renamed the Office of Strategic Programs and is playing a major role in implementing FDA’s patient-focused drug development initiative.
You may also be interested in...
FDA Meetings With Biosimilar Sponsors Aim To Make 351(k) Pathway OK
Short public meeting on the biosimilar user fee agreement suggests the proof will be in the scheduling.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.